Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of rAAV2-ND4 in LHON (RAVCT-2)
NCT01267422Phase 2Completed
- Start
- Apr 2011
- Primary completion
- Nov 2015
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of esonadogene mvoparvovec in Leber hereditary optic neuropathy (LHON). Primary endpoints: Best Corrected Visual Acuity at 3 years and CD3/CD4/CD8 Immune Cell Count at 6 months. Started Apr 2011; status: completed.
02
Drugs
esonadogene mvoparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT01267422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01267422.